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Abstract
Currently, immunotherapy is attracting a lot of attention and may potentially become a leading approach in the
treatment of cancer. One emerging therapeutic, the chimeric-antigen receptor T-cell adoptive immunotherapy (CAR-T)
is showing remarkable efﬁcacy in the treatment of several B-cell malignancies. The popularity of CAR-T has been
founded on two CAR T-cell products recently approved by FDA (during 2017) in the treatment of relapsed/refractory
B-cell acute lymphoblastic leukemia and B-cell lymphoma. However, their toxicities observed in clinical trials were
extremely signiﬁcant and in some cases even fatal with no approved algorithms for toxicity prediction being available
to date. A deeper understanding of the biological basis of such complications is the key to prompt and
comprehensive clinical management. Here we review the wide spectrum of effects associated with CAR T cell therapy
with a major focus on the pathogenesis of cytokine release syndrome and neurotoxicity as the most common,
potentially life-threatening effects of this treatment. We discuss the basis of clinical management and the existing
models that predict the severity of toxicity, as well as the key factors that modulate this event. Finally, we will
summarize the literature detailing universal allogenic CAR T-cells and their toxicity proﬁle.
Facts
1. The chimeric-antigen receptor T-cell adoptive
immunotherapy (CAR-T) is a potent instrument for
treating several hematological malignancies, not only
those expressing the CD19 receptor.
2. There is a pressing need to make this therapy
available to a wider spectrum of patients.
3. However, although the safety levels of CAR-T
therapy are generally acceptable, several fatal
outcomes due to severe cytotoxicity have been
reported in clinical trials of CAR-T therapies.
4. Therefore, better understanding of the spectrum of
toxicities, their etiology and pathogenesis as well as
the knowledge of toxicity-promoting factors may
help develop and validate the predictive scales and
deﬁne better prophylactic strategies for high-risk
patients.
Open questions
It is known that some of the factors that worsen the
toxicity of CAR-T therapy (higher CAR T-cell dose,
intensive lymphodepletion) also positively affect its efﬁ-
cacy. How can one achieve the proper balance between
these?
What kind of predictive model one should use for the
toxicity risk assessment and which group of patients
should be given the treatment for prophylaxis of such
toxicity?
Would universal allogenic CAR T-cells be as safe and
effective as the autologous CAR T-cells?
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